DOV said that the drug candidates DOV 21,947 and DOV 216,303, have been terminated by the parties effective December 6, 2006. New Jersey-based DOV said that it will regain all rights to the compounds, which will enable the company to increase its focus on its reuptake inhibitor program.
DOV, which is focused on the development of novel drug candidates for central nervous system disorders, said that there are no payments due to Merck.